Preface
Atrial fibrillation is gaining attention from the medical community as its epidemiological weight rises. It is no longer perceived as an unavoidable fate that either worsens the existing heart disease or appears as a lone arrhythmia with little likelihood of cure. The scene is changing. It is time to design further clinical studies primarily focused on atrial fibrillation. Measurement of outcome in the therapy of atrial fibrillation needs new consensus. Ablation of atrial fibrillation is an option now available to more and more patients, though clarification of techniques, outcomes, and risks is necessary. Finally, atrial fibrillation may be the expression of failure to adequately treat cardiovascular risk factors or heart disease. In the present issue, these considerations are expanded by an outstanding panel of authors. At present, it is not possible to forego knowledge of the new approaches towards atrial fibrillation.
![]()
CiteULike
Connotea
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||